New Cellular Map May Help Predict Crohn’s Disease Course in Children

Clinicians must decide early between steroids, immune‑modulating drugs, and antibodies targeting tumor necrosis factor‑alpha (TNFα)., yet responses vary and resistance can emerge. Better biomarkers to forecast severity and therapeutic benefit could prevent ineffective care and complications. A new study shows that a single‑cell map of pediatric Crohn’s disease can stratify disease and anticipate response to anti‑TNF therapy.

Boston Children’s Hospital and collaborating centers created high‑resolution single‑cell atlases of newly diagnosed pediatric Crohn’s disease and non‑inflammatory functional gastrointestinal disorders. The team also developed ARBOL, a publicly available bioinformatics tool that recursively partitions data to build trees of cellular states. Published previously as a Reviewed Preprint in eLife and appearing today as the final Version of Record, the work was described by the journal’s editors as an important advance supported by rigorous methodology.

Using single‑cell RNA sequencing (scRNA‑seq), researchers profiled diagnostic small‑intestine biopsies from 14 untreated children with Crohn’s disease, repeat biopsies from eight of these children after treatment, and 13 biopsies from a control group with functional gastrointestinal disorders. Anti‑tumor necrosis factor‑alpha (anti‑TNFα)–treated patients were separated into complete or partial responders, enabling correlation of outcomes with cell states at diagnosis. The pediCD atlas and the FGID atlas comprised 94,451 and 107,432 cells, respectively, and revealed discrete signatures linked to disease course.

More severe disease correlated with expansion of proinflammatory immune populations, including T cells, cytotoxic natural killer cells, and subsets of monocytes and macrophages, alongside depletion of metabolically specialized epithelial subsets. Significant diagnostic‑stage cell changes paralleled clinically observed severity and influenced decisions about initiating anti‑TNFα therapy. Integrating pediatric follow‑up data with an adult Crohn’s single‑cell atlas indicated that anti‑TNF exposure in children shifts the cellular ecosystem toward the more severe, treatment‑resistant state often seen in adult disease.

Institutions involved in the study include Boston Children’s Hospital; Dana‑Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School; Seattle Children’s; the University of Washington School of Medicine; the University of Chicago; and the Massachusetts Institute of Technology. The authors note limitations, including cohort size, strict inclusion and exclusion criteria, the follow‑up interval, and the difficulty of sampling untreated patients early in their diagnostic journey. They also could not directly relate genetic and environmental influences such as the enteric microbiome, infections, or dietary factors, and the cohort reflects Seattle‑area demographics.

“While targeting TNF is shared across many autoimmune and inflammatory conditions, it is not successful in all patients, and many go on to develop TNF-resistant disease. It’s of tremendous importance to understand for which patients TNF therapy is not necessary, in which patients it may help to control disease, and which patients are not likely to benefit at all,” said Kyle Kimler, Senior Data Scientist in the Cell Discovery Network at Boston Children’s Hospital.

“It will be essential to understand how both FGID and IBD may present differently in patients across the world and the influences involved. Future studies will need to include multiple cohorts to help uncover more location-specific and generalizable insights into these diseases,” said Jose Ordovas-Montanes, Associate Professor in the Division of Gastroenterology, Hepatology, and Nutrition at Boston Children’s Hospital and Harvard Medical School.

Related Links:
Boston Children’s Hospital